VCEL

Company Overview — What Does Vericel Corp Do?

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. Vericel Corp (VCEL) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Dominick C. Colangelo and employs approximately 300 people, headquartered in Ann Arbor, Massachusetts. With a market capitalization of $1.7B, VCEL is one of the notable companies in the Healthcare sector.

Vericel Corp (VCEL) Stock Rating — Reduce (April 2026)

As of April 2026, Vericel Corp receives a Reduce rating with a composite score of 40.6/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.VCEL ranks #2,149 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Vericel Corp ranks #246 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

VCEL Stock Price and 52-Week Range

Vericel Corp (VCEL) currently trades at $33.70. The stock gained $0.11 (0.3%) in the most recent trading session. The 52-week high for VCEL is $48.74, which means the stock is currently trading -30.9% from its annual peak. The 52-week low is $29.24, putting the stock 15.3% above its annual trough. Recent trading volume was 240K shares, suggesting relatively thin trading activity.

Is VCEL Overvalued or Undervalued? — Valuation Analysis

Vericel Corp (VCEL) carries a value factor score of 41/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 101.79x, compared to the Healthcare sector average of 23.63x — a premium of 331%. The price-to-book ratio stands at 4.79x, versus the sector average of 2.75x. The price-to-sales ratio is 7.04x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, VCEL trades at 38.43x EV/EBITDA, versus 6.34x for the sector.

Overall, VCEL's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

Vericel Corp Profitability — ROE, Margins, and Quality Score

Vericel Corp (VCEL) earns a quality factor score of 43/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -2.1%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -1.6% versus the sector average of -33.1%.

On a margin basis, Vericel Corp reports gross margins of 72.0%, compared to 71.5% for the sector. The operating margin is -6.7% (sector: -66.1%). Net profit margin stands at -4.1%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 28.2% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

VCEL Debt, Balance Sheet, and Financial Health

Vericel Corp has a debt-to-equity ratio of 38.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 5.03x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $100M.

VCEL has a beta of 1.18, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Vericel Corp is 50/100, reflecting average volatility within the normal range for its sector.

Vericel Corp Revenue and Earnings History — Quarterly Trend

In TTM 2026, Vericel Corp reported revenue of $241M and earnings per share (EPS) of $0.33. Net income for the quarter was $-8M. Gross margin was 72.0%. Operating income came in at $-14M.

In FY 2025, Vericel Corp reported revenue of $276M and earnings per share (EPS) of $0.33. Net income for the quarter was $17M. Gross margin was 74.4%. Revenue grew 16.5% year-over-year compared to FY 2024. Operating income came in at $11M.

In Q3 2025, Vericel Corp reported revenue of $68M and earnings per share (EPS) of $0.10. Net income for the quarter was $5M. Gross margin was 73.5%. Revenue grew 16.6% year-over-year compared to Q3 2024. Operating income came in at $3M.

In Q2 2025, Vericel Corp reported revenue of $63M and earnings per share (EPS) of $-0.01. Net income for the quarter was $-553,000. Gross margin was 73.7%. Revenue grew 20.1% year-over-year compared to Q2 2024. Operating income came in at $-2M.

Over the past 8 quarters, Vericel Corp has demonstrated a growth trajectory, with revenue expanding from $53M to $241M. Investors analyzing VCEL stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

VCEL Dividend Yield and Income Analysis

Vericel Corp (VCEL) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

VCEL Momentum and Technical Analysis Profile

Vericel Corp (VCEL) has a momentum factor score of 36/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 24/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 54/100 reflects moderate short selling activity.

VCEL vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Vericel Corp (VCEL) ranks #246 out of 838 stocks based on the Blank Capital composite score. This places VCEL in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing VCEL against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full VCEL vs S&P 500 (SPY) comparison to assess how Vericel Corp stacks up against the broader market across all factor dimensions.

VCEL Next Earnings Date

No upcoming earnings date has been announced for Vericel Corp (VCEL) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy VCEL? — Investment Thesis Summary

The quantitative profile for Vericel Corp suggests caution. Momentum is weak at 36/100, a headwind for near-term performance.

In summary, Vericel Corp (VCEL) earns a Reduce rating with a composite score of 40.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on VCEL stock.

Related Resources for VCEL Investors

Explore more research and tools: VCEL vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare VCEL head-to-head with peers: VCEL vs AZN, VCEL vs SLGL, VCEL vs VMD.